The chances to develop Alzheimer's disease (AD) result from a combination of genetic and non-genetic risk factors 1 , the latter likely being mediated by epigenetic mechanisms 2 . In the past, genome-wide association studies (GWAS) have identified an important number of risk loci associated with AD pathology 3 , but a causal relationship remains difficult to establish. In contrast, locus-specific or epigenome-wide association studies (EWAS) have revealed site-specific epigenetic alterations, which provide mechanistic insights for a particular risk gene but often lack the statistical power of GWAS
. Here, combining both approaches, we report a previously unidentified association of the peptidase M20-domain-containing protein 1 (PM20D1) with AD. We find that PM20D1 is a methylation and expression quantitative trait locus coupled to an AD-risk associated haplotype, which displays enhancer-like characteristics and contacts the PM20D1 promoter via a haplotype-dependent, CCCTC-binding-factor-mediated chromatin loop. Furthermore, PM20D1 is increased following AD-related neurotoxic insults at symptomatic stages in the APP/PS1 mouse model of AD and in human patients with AD who are carriers of the non-risk haplotype. In line, genetically increasing or decreasing the expression of PM20D1 reduces and aggravates AD-related pathologies, respectively. These findings suggest that in a particular genetic background, PM20D1 contributes to neuroprotection against AD.
Over the last decade, the number of epigenomic studies for AD has rapidly increased, which has been paralleled by the discovery of an increasing number of epigenetically dysregulated genes 5 . Despite that, only few such genes have been reported by independent studies in humans (i.e., ankyrin 1 (ANK1) 6, 7 , sorbin and SH3-domain-containing 3 (SORBS3) 8, 9 and histone deacetylase 2 (HDAC2) 10, 11 ). Contributing to this discrepancy is the complex heterogeneity of the nervous system, in which intra-individual epigenetic, as well as inter-individual genetic and epigenetic variability, call for more refined and integrative studies 5 . By combining epigenetic with genetic approaches, it has recently become possible to identify single-nucleotide polymorphisms (SNPs) that correlate with alterations in DNA methylation levels-so-called methylation quantitative trait loci (mQTLs)-the importance of which has just started to be recognized for complex diseases 4 . mQTLs have been reported for several neurological disorders, including schizophrenia 12 , obsessive-compulsive 13 and bipolar disorders 14 , but (as of now) not for neurodegenerative diseases such as AD.
In two recent EWAS 15, 16 we investigated DNA methylome changes in a panel of samples from patients with neurodegenerative diseases, including Parkinson's disease (PD), Lewy body dementia, as well as AD at different disease stages, and in two major affected brain areas, the hippocampus and the frontal cortex. When we re-analyzed these biologically and technically independent datasets by focusing exclusively on the comparison between samples from healthy controls and patients with advanced-stage AD, we noted that only one gene, PM20D1, which was previously described as a mQTL 17 , consistently displayed promoter hypermethylation in patients with AD (hereafter referred to as AD samples) than in healthy controls in both studies (Fig. 1a and Supplementary Tables 1  and 2 ). Confirming this observation, a meta-analysis of publicly available DNA methylation datasets (GSE45775, GSE57361, GSE59685, GSE76105 and GSE80970) found an enrichment of PM20D1 hypermethylation in AD samples (Fig. 1b,c) .
To further investigate the association between the PM20D1 mQTL and AD, we first selected SNPs that significantly correlated with PM20D1 DNA methylation, by using a recently described mQTL mapping tool 12 (Supplementary Table 3) , and examined their relation with AD by using a publicly available database from a National Center for Biotechnology Information (NCBI) GWAS (phs000168.v1.p1, National Institute on Aging (NIA)). We detected an allele-dose-dependent association with AD for most PM20D1 mQTL-associated SNPs (Supplementary Table 3 ). The highest significance was observed for SNPs rs708727 (P < 0.0001) and rs960603 (P = 0.0005), which co-segregated as a haplotype in nearly 85% of cases according to the 1000 Genomes project (phase-3-phased haplotypes for CEU population (Utah residents with Northern and Western European ancestry); rs708727 A frequency 0.40; rs960603 A frequency 0.45)
18
. Because the PM20D1 region is poorly represented and in low linkage disequilibrium with the SNPs interrogated in most of the GWAS arrays, which can differ between PM20D1 is a quantitative trait locus associated with Alzheimer's disease Fig. 1 | Overview of the PM20D1 locus and its relation to AD in human frontal cortex. a, The region comprises several genes (blue arrows) and is in partial linkage disequilibrium (HapMap CEU Recombination map is indicated below the genes). PM20D1 mQTLs reflected in Supplementary Table 3 are indicated in black, of which the mQTLs most strongly associated with AD are in bold magenta (rs708727) and bold red (rs960603). The top ten eQTLs in linkage disequilibrium with rs708727 (magenta) and rs960603 (red) obtained from GTEx database (GTEx consortium, neuronal origin tissues-hippocampus and tibial nerve) are also indicated. The differentially methylated region (DMR) on PM20D1 promoter is represented in magenta. b, Left, representative heat map (GSE80970) showing the presence of three main methylation groups in publically available datasets from control and AD IV-VI brain samples using two independent CpG probes-cg1165913 (CpG1) and cg14893161 (CpG2)-targeting sequences in the PM20D1 promoter. Magenta and green indicate high and low levels of DNA methylation in human frontal cortex samples, respectively. Right, centroid-based clustering (K-means) show three main groupsunmethylated (UM), heterozygous methylated (HM) and methylated (M) samples-with a higher prevalence of AD samples (n = 197; black line) in the methylated groups than control samples (Cont, n = 170; gray line). c, Cumulative M haplotype distribution of the data in b among control and AD groups (n = 734 haplotypes; P = 0.0083 by two-sided Chi-square test). **P < 0.01. d, rs708727 correlates with the levels of PM20D1 DNA methylation in human frontal cortex, as measured by pyrosequencing (n = 38 biologically independent human brain samples). Data are presented as box plots with minimum, first quartile, median, third quartile and maximum. Single values are represented by circles. P < 0.0001 by Pearson correlation. e, rs960603 correlates with the levels of PM20D1 DNA methylation in human frontal cortex, as measured by pyrosequencing (n = 34 biologically independent human brain samples). Data are presented as box plots with minimum, first quartile, median, third quartile and maximum. Single values are represented by circles. P = 0.0008 by Pearson correlation. f, PM20D1 RNA expression is inversely correlated with PM20D1 promoter DNA methylation in human frontal cortex samples, as measured by quantitative real-time PCR and pyrosequencing, respectively (n = 36 biologically independent human brain samples). Data are presented as box plots with minimum, first quartile, median, third quartile and maximum. Single values are represented by circles. P = 0.0005 by Pearson correlation. g, rs1361754 is located in the coding region of PM20D1 and is in linkage disequilibrium with rs708727. RT-PCR Sanger sequencing of rs1361754 heterozygous samples (n = 3) detected rs1361754 (T) but not rs1361754 (C) RNA transcripts, indicating that only the rs708727 (G) chromosome was active. h, rs708727 is located in the coding region of SLC41A1. RT-PCR Sanger sequencing of rs708727 heterozygous samples (n = 3) detected both alleles in RNA transcripts, indicating that both chromosomes were active. i, Representative whole-genome bisulfite sequencing analysis of DNA methylation in one GG (UM: GSM1173772) and one GA (HM: HM GSM1380998) rs707827 human frontal cortex sample. Differences in DNA methylation are restricted to the DMR region detected in the PM20D1 promoter. Circles represent CpG sequencing reads. Methylation average is represented by smoothed lines, and 95% confidence intervals are represented by shadows. j, Locus-specific bisulfite sequencing of PM20D1 region confirming the whole-genome bisulfite sequencing and pyrosequencing data (n = 3).
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We then assessed the relationship between the rs708727-rs960603 haplotype and PM20D1 DNA methylation in human frontal cortex brain samples. We observed an allele-dependent correlation with PM20D1 promoter methylation (Fig. 1d,e) , and further, that PM20D1 expression was inversely correlated with the methylation of its promoter (Fig. 1f) . Notably, PM20D1 expression was only detected from rs708727-rs960603 G-C chromosomes in heterozygous samples indicating that PM20D1 was mono-allelically expressed (Fig. 1g) . Supporting these observations, rs708727 and rs960603, as well as other mQTL SNPs and the SNPs in linkage disequilibrium with them ( Fig. 1a) , have previously been described as PM20D1 expression quantitative trait loci (eQTLs) 21 (Supplementary Table 3 ). Of note, although rs708727 is located in the coding region of solute carrier family 41 member 1 (SLC41A1), rs708727 does not change its protein sequence, and its expression can be detected from both chromosomes (Fig. 1h) . Accordingly, SLC41A1 does not show differences in DNA methylation either (Fig. 1i,j) . Lastly, the observed pattern in PM20D1 methylation between AD and control samples could not be explained by an altered neuron-glia ratio typical for AD, as gray-and white-matter samples from the same samples did not show DNA methylation differences ( Supplementary Fig. 1 ). Taken together, these data point to an association between PM20D1 hypermethylation and AD and further show that PM20D1 methylation and expression are dependent on the rs708727-rs960603 haplotype.
Proper control of gene expression often relies on distal cis-regulatory elements that come into physical contact with a gene's promoter region [22] . To better understand the molecular relationship between this rs798727-rs960603 haplotype and PM20D1 expression, we immortalized B cells from different genetic haplotypes (hereafter referred to as unmethylated (UM) and methylated (M) cells for the GG-CC and AA-TT rs708727-rs960603 samples), which show similar SNP-dependent DNA methylation and expression levels of PM20D1 as the human brain samples ( Supplementary  Fig. 2a ,b) and conducted chromatin-conformation capture assays (3C). We found that PM20D1 and its putative regulatory region rs708727-rs960603 interact, but that this interaction was haplotypedependent, i.e., it was weakened in the PM20D1 transcriptionally silent M cells (Fig. 2a) . Next we used chromatin immunoprecipitation (ChIP) assays to probe for the binding of CCCTC-binding factor (CTCF), which is responsible for more than 90% of DNA loops in mammalian genomes 23 . Consistent with the 3C results, CTCF showed reduced binding to both 3C anchors in M cells (Fig. 2b,c) . We also detected increased binding of methyl-CpG-binding protein 2 (MeCP2) and decreased histone acetylation-two hallmarks of a compacted, transcriptionally silent chromatin state in DNAmethylated regions 24 -in the PM20D1 promoter in M cells (Fig. 2d ,e and Supplementary Fig. 2c,d ). These epigenetic modifications were functionally important, as treatment with the DNA demethylating agent 5-azacytidine-dC in combination with the HDAC inhibitor valproic acid not only restored the DNA methylation and histone acetylation changes (Supplementary Fig. 3a-d ) but also the chromatin loop ( Supplementary Fig. 3e ) and PM20D1 RNA expression ( Supplementary Fig. 3f ).
Recent evidence suggests that disease-associated SNPs often affect the proper functioning of enhancers 25 . Using the Dragon ENhancers database (DENdb) 26 , we discovered a predicted enhancer region in proximity to the 3C 5′ locus ( Supplementary  Fig. 4 ). Consistent with these in silico data, we found increased levels of the enhancer-enriched epigenetic marks monomethylated Lys4 on histone H3 (H3K4me1) and acetylated Lys27 on histone H3 (H3K27ac) 27 in this region, but only in UM cells, which are not methylated at the PM20D1 promoter (Fig. 2f,g ). Of note, this finding was reminiscent of cell lines that displayed differential DNA methylation at the PM20D1 promoter, which also showed an accumulation for H3K4me1 and H3K27ac in the enhancer region 28 ( Supplementary Fig. 4) . Lastly, to test whether this region has transcription-altering properties, we performed luciferase reporter assays and observed a significant increase in luciferase activity in the presence of the predicted enhancer (Fig. 2h) . Taken together, these experiments testify to a haplotype-dependent three-dimensional chromatin interaction between the 3C 5′ locus, with enhancer-like characteristics, and the promoter region of PM20D1, which displays loop-dependent differential expression.
On the basis of the newly described differential expression of PM20D1 according to haplotype and AD risk we showed here, we next investigated whether PM20D1 might be related to the pathophysiology of AD, by using a combination of in vitro, mouse in vivo and postmortem human studies. In SH-SY5Y neuroblastoma cells, PM20D1 expression was increased after treatment with AD-related neurotoxic insults, such as reactive oxygen species (ROS) and amyloid-β (Aβ ) 1 (Fig. 3a) . In the APP/PS1 mouse model 29 of AD, which develops AD-related pathologies such as amyloid plaques, astrogliosis and learning deficits starting at seven months of age (and all of which increase with age) 30 , PM20D1 expression was higher in the frontal cortex at symptomatic stages, as compared to that in the pre-symptomatic stages and in age-matched control mice (Fig. 3b) . In human frontal cortex brain samples, we analyzed PM20D1 expression after correcting for the rs708727-rs960603 haplotype and found that PM20D1 expression was increased in non-risk haplotype carriers with AD compared to non-risk haplotype carriers without AD (Fig. 3c) . Consistent with this observation, a meta-analysis of publicly available RNA expression datasets (GSE33000, GSE15222 and GSE36980) showed an increase in PM20D1 expression in rs708727-rs960603-haplotype-corrected samples ( Supplementary Fig. 5a ). In contrast, PM20D1 expression was decreased in non-haplotype-corrected samples ( Supplementary  Fig. 5b ), which also show an enrichment of PM20D1-repressed samples in AD (Supplementary Fig. 5c ). Notably, PM20D1 expression, as measured by immunohistochemistry (IHC), was associated with glia-like cells surrounding neuritic plaques in APP/PS1 mice ( Supplementary Fig. 6 ) and in human AD samples (Fig. 3d) .
Finally, we genetically manipulated PM20D1 levels by using both virus-mediated PM20D1 overexpression and antisense oligonucleotides (ASOs) to mimic elevated and reduced PM20D1 levels, respectively. In vitro, we overexpressed PM20D1 in SH-SY5Y cells and in primary hippocampal cultures from APP/PS1 mice by using lentiviral constructs and assessed ROS-induced cell death and soluble Aβ levels, respectively. PM20D1 overexpression decreased ROSinduced cell death ( Supplementary Fig. 7a ), and in primary cultures, in which we found PM20D1 to be actively secreted ( Supplementary  Fig. 7b ), its overexpression reduced Aβ levels as compared to that of control-virus-infected cultures (Supplementary Fig. 7c ). In vivo, we overexpressed PM20D1 by using adeno-associated virus (AAV) vectors that were stereotaxically delivered to the hippocampus and repressed PM20D1 levels by using intracerebroventricular (ICV) injections of ASOs. AAV vectors and ASOs were injected in asymptomatic 3-month-old APP/PS1 mice, and memory performance and amyloid-related pathology were assayed 3 months later by the novel object recognition (NOR) test and by IHC (Fig. 3e) . We found that PM20D1 overexpression (AAV.Mock: n = 8; 0.18 ± 0.05 versus AAV.PM20D1: n = 10; 544.91 ± 216.48, mean ± s.e.m. for PM20D1 RNA levels; P < 0.05 by one-tailed Student's t-test) reduced amyloid plaque load (Fig. 3f,g ) and improved NOR performance (Fig. 3h) .Conversely, PM20D1 repression (ASO.Scramble: n = 12; 1.00 ± 0.11 versus AAV.PM20D1: n = 12; 0.76 ± 0.05, mean ± s.e.m. for PM20D1 RNA levels; P < 0.05 by one-tailed Student's t-test) increased amyloid plaque load (Fig. 3i,j) and impaired NOR performance (Fig. 3k) . Taken together, these data describe a Letters NATurE MEDICINE previously unknown, protective role for PM20D1 in the progression of AD-related pathologies.
In sum, we provide evidence for a mQTL-eQTL centered on PM20D1 that is implicated in AD. Independent analyses of DNA methylation and RNA expression show a significant enrichment of PM20D1 repression in AD, which we found to be linked via a CTCF-mediated chromatin loop to an AD-associated haplotype. Functionally, PM20D1 expression was stimulated by neurotoxic insults both in vitro and in vivo, whereas its overexpression reduced cell death, decreased Aβ levels and improved cognitive performance. Therefore, elevated levels of PM20D1 might provide a potential cellular defense mechanism for AD non-risk-haplotype carriers 
s t-test)
. e, ChIP assays showing that the PM20D1 promoter region of M samples is depleted of H3K9ac (n = 3 independent experiments; P = 0.0097 by one-sided Student's t-test). f, ChIP assays showing that H3K4me1 is enriched in UM samples in the 3C 5′ locus (n = 4 independent experiments; P = 0.0037 by one-sided Student's t-test). g, ChIP assays showing that H3K27ac is enriched in UM samples in the 3C 5′ locus (n = 4 independent experiments; P = 0.0081 by one-sided Student's t-test). h, DENdb predicted enhancer region capacity was assayed by cloning the region into a pGL4 promoter plasmid and measuring luciferase activity (n = 8 independent experiments; P < 0.0001 by one-sided Student's t-test). Throughout, 3C, ChIP and luciferase reporter assay data are presented as mean ± s.e.m. (a-h) ; single values are represented by circles (b-h). *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
Letters
NATurE MEDICINE In the presence of AD-related stress (red lightning bolt), such as the presence of ROS and Aβ , PM20D1 expression is enhanced and found to surround amyloid plaques, which reduces ROS-induced cell death and Aβ levels and prevents memory impairment (green box, right). In contrast, in samples with hypermethylated PM20D1 (red box; left; black circles represent methylated CpG sites), the promoter region of PM20D1 is not contacted by the enhancer region, PM20D1 transcription does not occur, and there is no protective effect against Aβ . Throughout, single values are represented by circles (a-c,g-k). *P < 0.05 and **P < 0.01.
NATurE MEDICINE (Fig. 3l) . Of note, PM20D1 has recently been associated with obesity [31] [32] [33] and diabetes 31, 33 , which are themselves risk factors for AD 34 . Furthermore, PM20D1 has been reported to be differentially methylated in individuals with obesity 32 or multiple sclerosis 35 , and it lies within the PD 16 (susceptibility) (PARK16) locus on chromosome 1, which has previously been associated with Parkinson's disease 36 . Whether PM20D1 behaves as an epistatic and/or pleiotropic trait across these conditions, as well as its precise mode of action, now require further investigation.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0013-y.
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Methods EWAS data. EWAS public data were obtained from the NCBI Gene Expression Omnibus (GEO) database (GSE45775 and GSE57361) and analyzed using R software (http://www.R-project.org), as previously described 15, 16 . Briefly, GSE45775 Infinium HumanMethylation27 BeadArray 27K (Illumina) data were quantilenormalized using the 'lumi' package and analyzed with the 'genefilter' package (Bioconductor). DMRs were defined by two or more probes that consistently reported changes in DNA methylation. GSE57361 whole-genome bisulfite sequencing data were aligned using Bismark software 37 and analyzed with the SAMtools 38 , bedtools 39 , Tabix 40 and ggplot2 packages. DMRs were identified by seeking regions with more than five consecutive CpG sites that were consistently located outside the 95% confidence interval of the smoothed methylation profile. For the meta-analysis, available NCBI GEO DNA methylation data from control and AD brain samples (GSE45775 15 , GSE57361 16 , GSE59685 6 , GSE76105 41 and GSE80970 27 ) were further investigated. Samples were stratified in three segments according to the corresponding methylated (M), heterozygous methylated (HM) and nonmethylated (UM) samples-using the centroid-based clustering (K-means) method-for each of the studies independently. Then the cumulative distribution of the segments between the control and AD groups was analyzed by a Chi-square test. Second-order and two-neighbors smoothing was used to show the differential distribution of methylated samples between the controls and AD groups. Source codes are available upon request.
GWAS data. GWAS public data was obtained from NCBI GEO database (phs000168. v1.p1 NIA "Late-onset AD and National Cell Repository for AD Family Study", consisting of 607 families-1,516 affected and 1,306 unaffected). The GWAS NIALOAD dataset was selected based on the high frequency of methylated SNPs in the population and the direct interrogation of PM20D1 mQTL SNPs without imputation. Selected mQTL SNPs were extracted using PLIN v1.07 software 42 and the relation with AD by fitting a logistic regression via generalized estimation equation (GEE) in a family data under additive genetic model with phenotype as outcome 43 . Hardy-Weinberg equilibrium and allelic test were performed, as previously reported 44 . A linkage disequilibrium plot was obtained from the UCSC track for HapMap Release 24 CEU recombination map and HapMap Linkage Disequilibrium (phase 2) from Phased Genotypes. Haplotypes were obtained from a phase 3 1000 Genomes CEU population (http://phase3browser.1000genomes.org). Source codes are available upon request. before further examination. DNA and RNA from gray matter samples of frontal cortex were extracted for subsequent experiments. Only samples with a RNA integrity number (RIN) > 6.5, according to the RNA quality test on Agilent's 2100 bioanalyzer, were included in the study. These filtered samples were DNA and RNA from gray matter of frontal cortex samples (Brodmann area 9) of 22 controls (Braak 0-II; 32% female; age 64 ± 3 years, mean ± s.e.m.) and 23 with AD (Braak V-VI; 43% female; age 77 ± 2 years, mean ± s.e.m.), matched for age and gender.
Cell culture. Immortalized B cells 46 were cultured in RPMI 1640 medium (Gibco) supplemented with 10% FBS (Gibco), 100 μ /ml penicillin (Invitrogen) and 100 mg/ml streptomycin (Invitrogen) at 37 °C in a humidified atmosphere of 5% CO 2 . Three independent clones per genotype were used. SH-SY5Y neuroblastoma cells (ATCC) were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 20% FBS, 100 μ /ml penicillin and 100 mg/ml streptomycin at 37 °C in a humidified atmosphere of 5% CO 2 . SH-SY5Y cells were treated with 0.2% hydrogen peroxide (Merck) and with synthetic Aβ (amino acids 1-42)-derived diffusible ligands (ADDLs) (Abcam), prepared as previously described 47 , during 6 h H 2 O 2 and 24 h ADDL treatment, respectively.
Mice. APP/PS1 mice were maintained under standard animal housing conditions in a normal 12-h light-dark cycle with ad libitum access to food and water. All animal procedures were conducted according to the EPFL's and Switzerland's guidelines on animal welfare (cantonal animal experimentation authorization numbers VD2875 and VD3169).
Stereotaxic injections were performed using a glass pipette (intraMARK, 10-to 20-μ m tip diameter, Blaubrand, injection flow: 0.1 µ l/min) that was connected to a syringe and a stereotaxic micromanipulator (Kopf Instruments) in deeply anesthetized 3-month-old APP/PS1 male mice. After injection the capillary was left at the injection site for 5 min before slow withdrawal at 0.01 mm/s. Deep anesthesia was induced by subcutaneous injection of a mixture of fentanyl (0.05 mg/kg, Sintetica), midazolam (5 mg/kg, Actavis) and medetomidin (0.5 mg/kg, Orion Pharma). At the end of the surgical procedure an anesthesia reversal mix containing naloxone (1.2 mg/kg, Swissmedic), flumazenil (0.5 mg/kg, Actavis) and atipamezole (2.5 mg/kg, Orion Pharma) was injected subcutaneously, and the mice were kept warm for an additional 2 h and administered paracetamol (500 mg per 250 ml) in the drinking water for 5 d.
AAV (serotype 9) vectors encoding human PM20D1 (AAV.PM20D1) or a mock (AAV.Mock; empty vector) were bilaterally injected the AAV-containing saline solution (0.5 µ l per side) in the dorsal hippocampus (posterior: -2.00 mm; depth: -2.25 mm; lateral: ± 1.50 mm; coordinates adapted from the Paxinos Atlas).
ASO LNA GapmeR (Exiqon) 5′ -CGGAGACCGTAGCGAA-3′ (ASO.PM20D1) and ASO LNA GampeR 5′ -AACACGTCTATACGC-3′ (ASO.Scramble) were used to repress PM20D1 expression in APP/PS1 mice. We unilaterally injected 1 µ l of the ASO-containing Ca 2+ -and Mg
2+
-free PBS solution (2.5 µ g of ASO per animal) in the right ventricle (posterior: -0.3 mm; depth: -2.5 mm; lateral: 0.9 mm; coordinates adapted from the Paxinos Atlas). For both AAV and ASO treatments, all of the mice were randomly assigned to the treatment groups and included in the analysis, except for animals with clearly misplaced injection sites, as determined by reporter gene fluorescence and/or needle track localization.
Three months after the surgeries, the mice were handled 5 min/d during five consecutive days the week before the NOR test. On test day 1, mice were habituated for 10 min to the open arena. On the second day, mice were placed for 10 min in the arena with two identical objects, and the time exploring each object was automatically recorded (Ethovision, Noldus). On the third day, one of the two familiar objects was replaced by a novel object. The time exploring each of the objects was recorded, and an object recognition index was calculated as the time spent exploring the novel object divided by the total time spent exploring the two objects (RI = time novel /(time novel + time familiar object )).
DNA methylation. DNA was isolated from postmortem human brain samples by phenol-chloroform extraction and bisulphite-converted using the EZ DNA methylation kit (Zymo Research) according to published modifications 48 . Primers for bisulfite cloning and sequencing were designed using the Methyl Primer Express, version 1.0 (Applied Biosystems), and the PCR products were cloned in the pGEMT-easy sequencing vector (Promega) and Sanger-sequenced as previously described 49 . Primers for pyrosequencing were designed using the PyroMark assay design program, version 2.0.01.15 (Qiagen), and pyrosequencing reactions were analyzed with the PyroMark Q24 System version 2.0.6 (Qiagen), following the manufacturer's instructions. Primers for bisulfite cloning and sequencing and for pyrosequencing are listed in Supplementary Table 4. RNA expression. Total RNA purification and DNase treatment were performed using TRIzol (Invitrogen) and the Turbo DNA-Free kit (Ambion). RNA was reverse-transcribed by using the Thermoscript RT-PCR system (Invitrogen), and the PCR samples were run using the StepOnePlus Real-Time PCR System (Applied Biosystems) and SYBR Green PCR MasterMaster Mix (Applied Biosystems). PCR efficiencies were calculated by using standard dilutions and the LinReg software 50 , and three housekeeping genes (GUSB, RPL38 and TBP) were used for normalizing PCR signals. Primers are listed in Supplementary Table 4 . For the meta-analysis, available NCBI GEO RNA expression data from frontal cortex brain samples of control individuals and those with AD (GSE33000 51 , GSE15222 52 and GSE36980 53 ) were further investigated. Samples were stratified in three segments according to the corresponding levels of expression using the centroid-based clustering (K-means) method for each of the studies independently. Then, the cumulative distribution of the segments between the control and AD groups was analyzed by a Chi-square test. z-scores were used for comparing overall and stratified levels of expression between control subjects and those with AD. RNA expression datasets were selected based on the number of samples and the alienated frequency of observed/expected frequencies of alleles.
Chromatin conformation capture (3C) protocol. 3C was carried out as described elsewhere 54 . In brief, cells were cross-linked for 5 min with 2% formaldehyde, blocked for 5 min with 125 mM glycine and lysed using a hypotonic buffer solution (0.25 M sucrose, 25 mM KCl, 5 mM MgCl 2 , 20 mM Tris-HCl, pH 7.5). Nuclei were resuspended in CutSmart Buffer (New England Biolabs) and permeabilized with 0.2% Triton-X100. Chromatin was digested overnight with HindIII (New England Biolabs) and ligated overnight in diluted conditions with T4 DNA ligase (New England Biolabs). Cross-links were then reversed overnight at 65 °C with 200 mM NaCl and proteinase K treatment. DNA was phenol-chloroform purified, ethanol precipitated, and resuspended in TE. BAC RRP11-219P13 (CHORI) was used for assaying all potential 3C products and primer PCR efficiencies. DNA concentration and efficiency of proximity ligation were used for normalizing signals. Primers for 3C are listed in Supplementary Table 4 .
Chromatin immunoprecipitation (ChIP) assays. ChIP experiments were carried out as described previously [10] . Briefly, cells were cross-linked for 10 min with 1% formaldehyde and blocked for 5 min with 125 mM glycine; the cells were then lysed by using a cell lysis buffer (5 mM HEPES, 85 mM KCl, 0.5% NP40, pH 8). Nuclei were lysed with a nuclear lysis buffer (50 mM Tris-HCl, 10 mM EDTA, 1% SDS, pH 8) and sonicated to obtain DNA fragments ~300 bp in size (on average) with EpiSonic Multi-Functional Bioprocessor 1100 (EpiGentek). A total of 5-20 μ g per sample was used, and an overnight ChIP reaction was performed overnight at 4 °C with antibodies specific for H3K4me1 (Abcam), H3K9ac (Abcam), H3K14ac
